Physicians' Academy for Cardiovascular Education

Risks associated with hyperkalemia

10' education - Sep. 16, 2021 - Prof. Stefan Anker, MD, PhD

NOAC as possible treatment option in patients with AF after successful TAVI

5' education - Sep. 13, 2021 - Prof. Nicolas van Mieghem, MD, PhD

Why focus on Lp(a)?

10' education - Sep. 13, 2021 - Prof. Naveed Sattar, MD, PhD

Surgery vs. stenting with asymptomatic critical carotid artery stenosis

5' education - Sep. 7, 2021 - Prof. Freek Verheugt, MD, PhD

Changing the paradigm on LDL-c-lowering in high CV risk patients

10' education - Sep. 7, 2021 - Prof. Kausik Ray, MD

Non-steroidal MRA effective in reducing CV events in patients with diabetes and CKD

5' education - Aug. 31, 2021 - Prof. Bertram Pitt, MD

Switching to a salt substitute reduces risk of stroke, CV events and death

5' education - Aug. 31, 2021 - Prof. Bruce Neal, MD, PhD

Moving the field of medicine and science is a collective exercise

3' education - Aug. 29, 2021 - Prof. Stephan Achenbach, MD, president ESC

SGLT2 inhibitor benefits patients with HFpEF by reducing clinically meaningful CV events

3' education - Aug. 29, 2021 - Prof. Stefan Anker, MD, PhD

Ground-breaking HF trial with evidence for SGLT2i at EF>40%

3' education - Aug. 29, 2021 - Prof. Frank Ruschitzka, MD

CV outcomes reduced by nonsteroidal MRA in patients with diabetes and CKD

3' education - Aug. 28, 2021 - Kevin Damman, MD, PhD

Kidney and HF outcomes with SGLT2i across EF spectrum in HF

3' education - Aug. 28, 2021 - Prof. Rudolf de Boer, MD, PhD

What is new in the 2021 ESC HF guidelines regarding patients with EF>40%?

3' education - Aug. 27, 2021 - Prof. Carolyn Lam, MD, PhD

Exciting findings of a pooled analysis of two large HF trials with SGLT2i

3' education - Aug. 27, 2021 - Milton Packer, MD

Another chapter in the SGLT2i book

3' education - Aug. 27, 2021 - Prof. Rudolf de Boer, MD, PhD

Phenotypic clusters in HFpEF

5' education - July 28, 2021 - Alicia Uijl, PhD

Where do GLP-1RA fit in in current and future management of CKD?

10' education - July 26, 2021 - Frederik Persson, MD - Online CME

Treatment goals for patients with T2DM and CKD

10' education - July 13, 2021 - Prof. Peter Rossing, MD - Online CME

Continued benefit of statin treatment after stopping therapy

5' education - July 12, 2021 - Jackie Bosch, PhD

How can GLP-1RA benefit a patient with diabetes and CKD?

10' education - July 1, 2021 - Daniël van Raalte, MD, PhD - Online CME

Risks associated with hyperkalemia

10' education - Sep. 16, 2021 - Prof. Stefan Anker, MD, PhD
Hyperkalemia is a major clinical problem. Prof. Stefan Anker talks about problems and risk associated with hyperkalemia.

Hyperkalemia is a major clinical problem. Prof. Stefan Anker talks about problems and risk associated with hyperkalemia.

Low testing rates for iron deficiency in patients with HF

Literature - Sep. 15, 2021 - Becher PM et al. - Eur J Heart Fail. 2021

In SwedeHF, a nationwide HF registry in Sweden, approximately 1 in 4 patients with HF were tested for iron deficiency (ID). ID was present in half of the tested population. 1 in 5 patients with ID received ferric carboxymaltose.

Combination of NOAC plus aspirin in older PAD patients after limb revascularization

Literature - Sep. 15, 2021 - Krantz MJ, et al. - Eur Heart J. 2021

Low-dose rivaroxaban plus aspirin reduces ischemic limb and CV events in PAD patients after limb revascularization compared to aspirin alone, with consistent benefit in patients ≥75 years vs. <75 years. TIMI major bleedings were increased with rivaroxaban, regardless of age.

FDA Breakthrough Therapy Designation for SGLT2i in HFpEF

News - Sep. 14, 2021

The FDA has granted Breakthrough Therapy Designation to empagliflozin as an investigational treatment for patients with HFpEF, following the results from the EMPEROR-Preserved trial.

SGLT2 inhibitor reduces epicardial adipose tissue in nondiabetic patients with HFrEF

Literature - Sep. 13, 2021 - Requena-Ibáñez JA et al. - JACC Heart Fail. 2021

Empagliflozin significantly reduced epicardial adipose tissue, subcutaneous adipose tissue, myocardial extracellular volume, matrix volume, cardiomyocyte volume, aortic stiffness and several inflammatory biomarkers, compared to placebo in nondiabetic patients with HFrEF.

NOAC as possible treatment option in patients with AF after successful TAVI

5' education - Sep. 13, 2021 - Prof. Nicolas van Mieghem, MD, PhD
In the ENVISAGE-TAVI AF trial, the effect of edoxaban on net adverse clinical events (NACE)  was compared to VKAs in elderly patients with AF who underwent TAVI.

ESC 2021 In the ENVISAGE-TAVI AF trial, the effect of edoxaban on net adverse clinical events (NACE) was compared to VKAs in elderly patients with AF who underwent TAVI.

Global registry study shows that FH is diagnosed late and poorly managed

Literature - Sep. 13, 2021 - EAS Familial Hypercholesterolaemia Studies Collaboration (FHCS) - The Lancet 2021

The EAS FHSC have created a global registry of FH patients for the surveillance of FH worldwide. Findings of the present study on the adult population show that FH is diagnosed late and LDL-c targets are often not achieved.

Why focus on Lp(a)?

10' education - Sep. 13, 2021 - Prof. Naveed Sattar, MD, PhD
What is Lp(a), how common are high Lp(a) levels and what is the relationship with CV events? Prof. Sattar answers these questions in a brief overview.

What is Lp(a), how common are high Lp(a) levels and what is the relationship with CV events? Prof. Sattar answers these questions in a brief overview. With poll

Continued efficacy of LDL-c lowering, even below 40 mg/dL, in high risk patients

Literature - Sep. 8, 2021 - Marston NA et al. - Circulation 2021

An exploratory analysis of FOURIER showed that lowering of LDL-c by evolocumab below 40 mg/dL resulted in continued reduction of MACE in ASCVD patients.

Surgery vs. stenting with asymptomatic critical carotid artery stenosis

5' education - Sep. 7, 2021 - Prof. Freek Verheugt, MD, PhD
Which procedure is better when incidentally critical carotid artery stenosis is found; carotid surgery or stenting? Prof. Verheugt discusses findings of the ACST-2 trial.

ESC 2021 Which procedure is better when incidentally critical carotid artery stenosis is found; carotid surgery or stenting? Prof. Verheugt discusses findings of the ACST-2 trial.

NHS agreement on population health management approach using PCSK9 siRNA therapy

News - Sep. 7, 2021

The NHS has made an agreement on a population health management approach in those eligible for the PCSK9 siRNA inclisiran.

Starting with quarter-dose quadruple combination pill effectively lowers BP

News - Sep. 7, 2021

ESC 2021 The QUARTET trial showed that starting with a quarter-dose quadruple combination pill led to greater BP lowering compared to starting with standard dose monotherapy in patients with hypertension.